The development of new drugs to counter human immunodeficiency virus (HIV) infection has led to an increase in lipodystrophic syndrome among HIV-infected individuals receiving combination therapy. Bio-Alcamid(TM) is a recently developed polymeric substance that can be implanted to compensate for adipose effects. We have implanted this substance in 73 patients with up to three years' follow-up. The aesthetic results were deemed excellent by both physicians and patients. No implant dislocation, implant migration, granuloma, allergic reaction or intolerance were recorded.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/14764170310021922 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Preliminary experiences with Bio-Alcamid in HIV facial lipoatrophy.
Dermatology
May 2007
Department of Aesthetic Surgery, Elisha Hospital, Haifa, Israel.
Background: Highly active antiretroviral therapy for HIV-infected patients causes metabolic changes known as the lipodystrophy syndrome. Autologous fat injections, dermal fat grafts, malar implants and injected fillers have been reported as treatment options.
Objective: To evaluate the results of HIV-infected patients treated with Bio-Alcamid for facial lipoatrophy.
Bio-Alcamid in drug-induced lipodystrophy.
J Cosmet Laser Ther
December 2003
Department of Plastic Surgery, University of Parma, Parma, Italy.
The development of new drugs to counter human immunodeficiency virus (HIV) infection has led to an increase in lipodystrophic syndrome among HIV-infected individuals receiving combination therapy. Bio-Alcamid(TM) is a recently developed polymeric substance that can be implanted to compensate for adipose effects. We have implanted this substance in 73 patients with up to three years' follow-up.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!